FiercePharmaOriginal article
{"a":[{"_":"Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie","$":{"href":"/pharma/pfizer-taking-litfulo-regulators-vitiligo-challenge-incyte-abbvie","hreflang":"en"}}]}
NDA FilingLitfuloOpzeluraPositive
AI Analysis
Summary
Pfizer is submitting late-stage study results to regulators for Litfulo, an oral JAK inhibitor for nonsegmental vitiligo, aiming to compete with Incyte's topical Opzelura and AbbVie's offerings in the vitiligo market.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Pfizer submitting late-stage study results for oral JAK inhibitor Litfulo in nonsegmental vitiligo
Importance:6/10
Sentiment:
0.40
JAK inhibitorvitiligooral formulationregulatory submissioncompetitive threat
Related Companies
Read the original article
Published by FiercePharma on July 30, 2026 2:00 PM